The Effect of 6 and 12 months Duodenal-Jejunal Bypass Liner Treatment on Obesity and Type 2 Diabetes: a Crossover Cohort Study

por van Rijn, Selwyn, Betzel, Bark, de Jonge, Charlotte, van Dijk, David P. J., Janssen, Ignace M., Berends, Frits J., Bouvy, Nicole D., Greve, Jan Willem M.
Publicado 2017

Complement Alternative Pathway Activation in Human Nonalcoholic Steatohepatitis

por Segers, Filip M., Verdam, Froukje J., de Jonge, Charlotte, Boonen, Bas, Driessen, Ann, Shiri-Sverdlov, Ronit, Bouvy, Nicole D., Greve, Jan Willem M., Buurman, Wim A., Rensen, Sander S.
Publicado 2014

Endoscopic Duodenal-Jejunal Bypass Liner Treatment for Type 2 Diabetes and Obesity: Glycemic and Cardiovascular Disease Risk Factor Improvements in 1,022 Patients Treated Worldwide

por Ryder, Robert E.J., Laubner, Katharina, Benes, Marek, Haluzik, Martin, Munro, Lynne, Frydenberg, Harry, Teare, Julian P., Ruban, Aruchuna, Fishman, Sigal, Santo, Erwin, Stengel, Rainer, De Jonge, Charlotte, Greve, Jan W., Cohen, Ricardo V., Aboud, Cristina M., Holtmann, Gerald J., Rich, Graeme, McMaster, Jess J., Battelino, Tadej, Kotnik, Primoz, Byrne, James P., Mason, John C., Bessell, Justin, Bascomb, Jeanine, Kow, Lillian, Collins, Janes, Chisholm, Jacob, Pferschy, Peter N., Sourij, Harald, Cull, Melissa L., Wyres, Melanie C., Drummond, Russell, McGowan, Barbara, Amiel, Stephanie A., Yadagiri, Mahi, Sen Gupta, Piya, Aberle, Jens, Seufert, Jochen
Publicado 2023